Pharmaceutical Commerce Magazine

🚨Our December is LIVE🚨 Did industry fumble the #DSCSA deadline?▪️Breaking barriers to revolutionize patient services▪️Navigating the landscape of global #AI governance▪️and so much more right here ➡️ https://lnkd.in/eA35u5uP

Breaking Barriers in Patient Services! Maria Bucceri Kirsch explores critical challenges in patient care and how models like Direct-to-Patient (DTP) can revolutionize healthcare in this piece in Pharmaceutical Executive. Discover her insights for enhancing patient access, support, and engagement. Read more here https://lnkd.in/g9RZX3Ue #PatientCare #HealthcareInnovation

📍Coverage from Trade & Channel Strategies Conference 2024 Trade & Channel Strategies carried on, with a case study on how to “Navigate Pharmacy and Distribution Models for Market Access Mastery.” John Harlow, chief commercial officer at Melinta Therapeutics, offered perspective on ways to transform commercial organizations and drive revenue growth; how to effectively manage costs when it comes to specialty models; and the value of partnerships in terms of strategic planning and brand development.

📍Coverage from Trade & Channel Strategies Conference 2024 Day 1 of Trade & Channel Strategies in Philadelphia welcomed several captivating sessions, including a panel centered around “Pharmacy Evolved—Aligning Commercialization to the Changing Pharmacy Channel.” Tom Doyle, SVP of sales and chief customer officer for biopharma services at Cencora, the panel’s moderator, was joined by Tim Cernohous, the wholesaler’s SVP and president of community retail and long-term care pharmacy, and Karen Martell, Alto Pharmacy’s VP of enterprise partnerships.

📍Coverage from Trade & Channel Strategies Conference 2024 This year’s Trade & Channel Strategies Conference in Philadelphia kicked off with a keynote address from William Roth, SVP of IntegriChain’s consulting business, Blue Fin Group, an IntegriChain Company, and Pharmaceutical Commerce Magazine board member. Titled “Access and Channel 2024 Year-in-Review and Preview of 2025”, Roth discussed the current #reimbursement landscape, how the evolving site-of-care trends are shaping #patientaccess and channel dynamics, and the influence of cost of goods on channel strategies and profitability.

A thought-provoking day at #trade2024 to say the least! I recognized that many of Pharmaceutical Commerce Magazine EAB members are in the attendance, including Cheryl Allen, Blake Powers, and William Roth. Roth led off day 1 with a year-in-review and preview of 2025, and a stat that stuck out to me was that the average pharmacy abandonment rate in the retail market is 50% *mind blown.* He also noted the value in taking risks: "At some point, it's going to work, but you're not necessarily going to see it in the data." (More on this session from my colleague Donald Tracy, MA when he puts together the synopsis.) I also had the opportunity to moderate a panel (shoutout Allie Spica) on "Insights From Wall Street: Market Dynamics and Investment Considerations in Drug Commercialization, Distribution and Pharmacy," featuring Joyce Lau and Shawn Pelc, in which they wonderfully helped break down the market dynamics across specialty pharma, infusion, and distribution channels. Great feedback and great questions from the audience members too. Stay tuned for the rest of the session coverage that's to come throughout the week! MJH Life Sciences®

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts. 🖊️ Nick Basta

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.